News | October 04, 2013

Piramal Imaging Responds to CMS-Proposed Coverage Decision for Beta-Amyloid PET

October 4, 2013 — Piramal Imaging announced the company has submitted a detailed response to the Council on Medical Service (CMS) regarding the draft decision to limit Medicare coverage of beta-amyloid positron emission tomography (PET) imaging in dementia and neurodegenerative disease.[1] Piramal Imaging's response, originally submitted on July 29, 2013, was posted on CMS's website as part of the public comment process, which was open through August 2. As of August 8, CMS's website indicated more than 200 people had posted responses. Piramal Imaging strongly encourages the public to continue to submit evidence to CMS showing why beta-amyloid imaging is a medically necessary diagnostic tool for appropriate Medicare populations by sending information to [email protected].

In Piramal Imaging's letter to CMS, the company expressed concerns that the CMS draft coverage decision is overly restrictive and, if finalized in its current form, would place an undue burden on physicians, patients and caregivers by delaying the definitive diagnosis of certain types of dementia and neurodegenerative diseases, including Alzheimer's disease (AD).

The letter addresses four specific areas of concern and offers recommendations for consideration which are highlighted below:

  1. Agreement with CMS's determination that there is a clear benefit to rule out AD in precisely defined patient populations where a differential diagnosis is clinically difficult and to distinguish from other forms of dementia such as frontotemporal dementia. Piramal Imaging has requested Medicare coverage for these patients without requiring enrollment in a clinical trial. Clinical presentation of early onset AD can be difficult to distinguish from other forms of dementia and can present with many atypical features, which obfuscate the diagnosis. The results of beta-amyloid PET imaging thus can help the physician with the differential diagnosis of the patient, leading to identification of other appropriate treatments and tests to administer.[2] It can help the physician determine whether further testing is needed and to select pharmacologic and non-pharmacologic options for the patient's treatable conditions, and it may enable the patient to forgo potentially futile testing and treatment. Furthermore, Piramal Imaging believes there is a patient population for which beta-amyloid PET imaging meets the "reasonable and necessary" threshold for the diagnosis of disease: patients meeting the Appropriate Use Criteria (AUC) developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer's Association.
  2. CMS should establish a clear standard of the level of evidence required to expand coverage. CMS should approve any clinical trials that are likely to expeditiously answer one or several of the three proposed research questions without onerous restrictions. Furthermore, CMS should ensure that it approves a sufficient range of clinical trials, allowing for a variety of practical clinical trial designs, providing they address relevant endpoints and help answer all or at least one of CMS' research questions.
  3. CMS should state in its final decision memo that once a clinical trial meets endpoints as agreed upon by CMS, it will expand Medicare coverage in a corresponding manner without any undue delay. The decision to expand coverage based on the results of a successful clinical trial should not unnecessarily delay the National Coverage Determination process. Medicare beneficiaries should not lose access to diagnostic technologies that have demonstrated clinical benefits in patient outcomes.
  4. CMS should not require a postmortem autopsy as an endpoint for any CMS-approved clinical trial. Several pivotal autopsy studies demonstrate amyloid imaging agents bind to beta-amyloid in the brain; therefore, further biomarker studies are redundant. According to the Agency for Healthcare Research and Quality (AHRQ) Clinical Research Standard no. 3, "the research study does not unjustifiably duplicate existing studies." Therefore, additional post-mortem autopsy studies would not fulfill the above AHRQ standard. In addition, Medicare beneficiaries may understandably be very uncomfortable or unwilling to agree to such a requirement to undergo a diagnostic imaging scan.

 

For more information: imaging.piramalenterprises.com

 

References

[1]Centers for Medicare & Medicaid Services. Proposed decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). http://www.cms.gov/medicare-coverage-database/details/nca-proposed-decis.... Published July 3, 2013. Accessed August 8, 2013

[2]Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association [published online ahead of print January 28, 2013]. Alzheimer's Dement. doi:10.1016/j.jalz.2013.01.002

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Videos | Angiography | February 08, 2019
This is an example of an arterial venous malformation (AVM) in the brain imaged on a...
Medtronic Recalls Synergy Cranial Software and Stealth Station S7 Cranial Software
News | Procedure Navigation Systems | February 05, 2019
Medtronic is recalling the Synergy Cranial Software and StealthStation S7 Cranial Software used with the StealthStation...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
First Arterial and Venous Atlas of the Human Brain Released
News | Neuro Imaging | January 02, 2019
January 2, 2019 — Imagine an atlas containing an image bank of the blood vessels of the...